The cocktail, bamlanivimab and etesevimab, was authorized in
February for use in people 12 years and above with mild-to-moderate
infection and are at high risk for progression to severe COVID-19.
However, the FDA said on Thursday the cocktail is not a substitute
for vaccination against COVID-19. (https://bit.ly/2XqtHln)
The FDA said that bamlanivimab and etesevimab, which are
administered together, could be also used as post-exposure
prevention for patients who are not fully vaccinated or who are not
expected to mount an adequate immune response to complete
vaccination or have been exposed to an individual infected with the
[to top of second column]
The revision comes a day after
the U.S. government bought 388,000 additional
doses of Lilly's COVID-19 antibody therapy.
(Reporting by Dania Nadeem in Bengaluru; Editing
by Shailesh Kuber)
[© 2021 Thomson Reuters. All rights
Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content